Skip to content

Tomáš Páleníček

Charles University, National Institute of Mental Health

72 papers in the library · 2,946 citations · publishing 2007-2026

Papers

Sort Most recent Most cited

Psilocybin and Contrasting Musical Compositions: Effects on Music-Evoked Emotional Responses in Healthy Adults

medRxiv September 23, 2026 Dominika Dojčánová, Filip Tylš, Marek Nikolič et al. preprint

Music is a central component of psychedelic settings, yet little experimental work has examined how psilocybin and musical composition influence music-evoked emotional responses in healthy volunteers. This exploratory, double-blind, placebo-controlled study assessed these effects during the plateau phase of psilocybin and the corresponding time window in placebo sessions following oral...

Psilocybin-induced changes in electroencephalography link acute and long-term effects

Journal of Psychopharmacology September 4, 2026 Marek Nikolič, Tom Froese, Pedro A. M. Mediano et al.

Background: Psilocybin’s therapeutic potential is neurophysiologically characterized by acute alpha power reductions and increased entropy. However, the systematic time-course of these changes from administration through the 24-hour sub-acute phase remains poorly characterized. Methods: In a double-blind, placebo-controlled, crossover trial ( N = 20, 10 females), healthy participants received a...

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Journal of Affective Disorders August 1, 2026 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 2 citations

The contribution of patient support to psilocybin's antidepressant effects remains uncertain. Relationships between therapeutic alliance (Scale to Assess Therapeutic Relationship-Patient version; STAR-P), psychedelic experience (Five-Dimensional Altered States of Consciousness Questionnaire and Emotional Breakthrough Inventory; 5D-ASC and EBI) and clinical outcomes (Montgomery-Åsberg Depression...

Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions

Journal of Fungi July 2, 2026 Amiel Sharchaton, Shilat Parsha, Sara P. Azerrad et al.

Psilocybin-producing mushrooms exhibit considerable biochemical diversity, yet the extent of variability among strains within a single species under standardized conditions remains insufficiently characterized. In this study, we quantified psilocybin, psilocin, baeocystin, norbaeocystin, aeruginascin, and norpsilocin in the fruiting bodies of 14 distinct strains of Psilocybe cubensis. The...

DOI: 10.3390/jof12070486 (opens in new tab) Psilocybin Tryptamine Mushroom Strain injury +2

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, Biochemistry, and Behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

T-shaped expertise: rethinking interdisciplinarity in psychedelic research

Psychedelics June 28, 2026 Joost J. Breeksema, Ulf Bremberg, Jens H van Dalfsen et al.

The research, understanding, and implementation of psychedelic therapies is characterised by a layered complexity that arises from the dynamic interactions between pharmacological and extra-pharmacological factors, and the embeddedness of psychedelics within broader societal, legal, and regulatory systems ill-equipped to accommodate them. This complexity is compounded by an epistemic...

DOI: 10.1016/j.psyche.2026.100026 (opens in new tab) Operationalization Embeddedness Indigenous Complexity science +2

Integrating psychedelic-assisted psychotherapy into addiction care in the Czech Republic: Clinical evidence, safety, and regulatory developments

Journal of Psychedelic Studies June 12, 2026 Zuzana Postránecká, Matyáš Lucký, Viktor Mravčík et al.

Abstract The Czech Republic, like many European countries, continues to face significant challenges in treating substance use disorders (SUDs), with high relapse rates and complex comorbidities often linked to trauma and mental illness. Psychedelic-assisted psychotherapy (PAP) has re-emerged internationally as a promising therapeutic modality, although available evidence remains heterogeneous...

DOI: 10.1556/2054.2026.00514 (opens in new tab) Addiction treatment Psychological intervention Czech Inclusion mineral +9

EEG microstate dynamics during psilocybin intoxication relate to acute experience and persisting psychological changes

bioRxiv (Cold Spring Harbor Laboratory) June 12, 2026 Nikola Jajcay, Čestmír Vejmola, Jakub Korčák et al. preprint

Abstract Psilocybin and other serotonergic psychedelics show therapeutic promise for psychiatric disorders, yet objective neural correlates linking the acute psychedelic state to persisting psychological outcomes remain limited. Electroencephalography (EEG) microstate analysis characterizes the rapid spatiotemporal organization of large-scale brain activity, offering a millisecond-resolution...

Long term efficacy and safety of GH001 in patients with treatment-resistant depression

European Psychiatry June 1, 2026 Eduard Vieta, Bernhard T Baune, N. Cardoner et al.

Treatment-resistant depression (TRD), a persistent condition impacting up to 30% of patients with major depressive disorder, carries substantial personal and economic burden. There remains an unmet need for therapies that provide both rapid and durable improvements in TRD. Preliminary clinical trials indicate that GH001, a synthetic, inhalable formulation of mebufotenin, has the potential for...

Effects of THC, CBD, and Their Combination on EEG Dynamics in Rats.

Physiological research May 12, 2026 Marcel Bochin, Čestmír Vejmola, Vlastimil Koudelka et al.

Cannabinoids modulate brain network activity, yet the spatial organization and temporal evolution of their electrophysiological effects remain insufficiently characterized in animal models. Here, we investigated how acute oral administration of ?9-tetrahydrocannabinol (THC; 10 mg/kg), cannabidiol (CBD; 10 mg/kg), and their combination influences resting-state EEG dynamics in freely moving rats....

Serotonergic modulation of cortical gamma synchronization: right-lateralized psilocin effects on 40 Hz auditory steady-state responses in rats.

Journal of Neurophysiology April 1, 2026 Inga Griškova-bulanova, Čestmír Vejmola, Tomáš Páleníček

Auditory steady-state responses (ASSRs), particularly at 40 Hz, are promising biomarkers for psychiatric disorders involving dysregulated neural synchronization. Although most ASSR studies have focused on the glutamatergic system, the serotonergic system, specifically 5-HT2A receptor signaling, has received limited attention. Psilocin, the active metabolite of psilocybin and a known 5-HT2A...

DOI: 10.1152/jn.00519.2025 (opens in new tab) Full text (opens in new tab) Psilocin Auditory steady-state response Gamma oscillations Neural synchrony +1

GH001 vs Placebo in Patients With Treatment-Resistant Depression

JAMA Psychiatry March 25, 2026 Wiesław Jerzy Cubała, Malek Bajbouj, Michael Bauer et al. 3 citations

Importance: Few pharmacotherapies are approved for treatment-resistant depression, and many patients do not achieve remission following treatment with those therapies. Objective: To examine the efficacy and safety of single-day treatment with a synthetic formulation of inhaled mebufotenin (GH001) vs placebo in patients with treatment-resistant depression. Design, Setting, and Participants: This...

Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention

Addiction Biology March 1, 2026 Isis Koutrouli, Vojtěch Brejtr, Marek Schwendt et al.

Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Here, we investigated the effects of a clinically inspired dose-escalation protocol of psilocybin and ibogaine on extinction and cue-induced reinstatement in Wistar male rats following intravenous cocaine self-administration (IVSA). Rats were trained on...

DOI: 10.1111/adb.70111 (opens in new tab) Psilocybin Extinction optical mineralogy Hallucinogen Drug +2

The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures

Journal of Psychopharmacology 2026 Petr Scholle, Štěpán Wenke, Tereza Nekovářová et al. 1 citation

Background: Although psychedelics have regained attention as potential treatment tools for various mental disorders, little research has examined their impact on temporal perception. Aims: This double-blinded placebo-controlled study aimed to investigate changes in temporal perception under psilocybin, both through performance during the Temporal Bisection Task (TBT) and through subjective...

Regional specificity of the cingulate cortex thickness association with the intensity of psilocybin experience: a replication study

Psychopharmacology December 13, 2025 David Greguš, Jaroslav Hlinka, Filip Tylš et al.

Individual variability in psilocybin response is a major challenge for psychedelic-assisted therapy, with structural brain features potentially serving as predictive biomarkers. (Lewis et al. Biomedicines 8(2):34 2020) reported that rostral anterior cingulate cortex thickness predicted emotional experiences under psilocybin, suggesting cortical morphometry as a marker of psychedelic...

Regional Specificity of the Cingulate Cortex Thickness Association with the Intensity of Psilocybin Experience: A Replication Study

Research Square September 25, 2025 David Greguš, Jaroslav Hlinka, Filip Tylš et al. preprint

Abstract Rationale: Individual variability in psilocybin response is a major challenge for psychedelic-assisted therapy, with structural brain features potentially serving as predictive biomarkers. Lewis et al. (2020) reported that rostral anterior cingulate cortex thickness predicted emotional experiences under psilocybin, suggesting cortical morphometry as a marker of psychedelic...

Concomitant use of antidepressants and classic psychedelics: A scoping review

Journal of Psychopharmacology September 12, 2025 Stephan Tap, Kelan Thomas, Tomáš Páleníček et al. 5 citations

Classic psychedelics are increasingly studied as potential treatments for different psychiatric disorders. Current research protocols often require patients to discontinue antidepressants (ADs) for at least 2 weeks before psychedelic administration to decrease the risk of serotonin syndrome and limit their effect on efficacy and the acute subjective effects of psychedelics. Moreover, the...

Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats.

Biological Psychiatry Global Open Science September 1, 2025 Čestmír Vejmola, Klára Šíchová, Kateřina Syrová et al. 4 citations

Psychedelics, particularly psilocin, are increasingly being studied for their mind-altering effects and potential therapeutic applications in psychiatry. Visual hallucinations, especially the illusion of motion in static images, are a hallmark of their action. Despite growing interest, the underlying mechanisms remain poorly understood, as their systematic evaluation in both humans and animals...

Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats.

The International Journal of Neuropsychopharmacology August 1, 2025 Klára Šíchová, Barbara Mallarino, Lucie Janeckova et al. 1 citation

Hexahydrocannabinol (HHC) is a new psychoactive substance known for its mind-altering effects and temporary legal status. It is widely used in parts of the Europe and United Kingdom as a legal alternative to ∆9-tetrahydrocannabinol, yet little research has explored its effects and safety. This study examined how HHC is processed in the body, its toxicity, and its impact on behavior in male...

DOI: 10.1093/ijnp/pyaf041 (opens in new tab) Full text (opens in new tab) Acute toxicity Behavior Hexahydrocannabinol Pharmacokinetics +1

Behavioural and pharmacological evaluation of the psilocybin analogue baeocystin in Wistar rats.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 5, 2025 Hynek Danda, Kristýna Mazochová, Klára Šíchová et al. 1 citation

Baeocystin is a naturally occurring tryptamine-based compound found in various psychoactive mushrooms, including in several species of Psilocybe genus. Due to its structural similarity to psilocybin, which has shown a therapeutic potential in treatment of psychiatric disorders, there is a growing interest in investigating whether baeocystin exhibits comparable effects. This study investigated...

DOI: 10.1016/j.pnpbp.2025.111439 (opens in new tab) Full text (opens in new tab) Open field Pharmacokinetics Prepulse inhibition Wistar rats +2

What fMRI studies say about the nature of the psychedelic effect: a scoping review

Frontiers in Neuroscience July 1, 2025 Michal Beneš, Tomáš Páleníček, Jiřı́ Horáček 4 citations

Research on psychedelic drugs, such as psilocybin, LSD or DMT, is a burgeoning field, with an increasing number of studies showing their promise in treatment of mental disorders as well as examining their mechanism of action. Determining their effect on the brain is crucial from clinical standpoint, but also offers highly promising avenues of advancement in basic neuroscience—functional...

DOI: 10.3389/fnins.2025.1606798 (opens in new tab) Psilocybin Serotonergic Cognitive psychology Modality human–computer interaction +1

The phenomenology of psilocybin's experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting.

Pharmacological Reports June 16, 2025 Tereza Klučková, Marek Nikolič, Filip Tylš et al. 4 citations

Recent studies intensively explore psilocybin's antidepressant potential, but variables like previous experience, repeated use, setting, and sex remain underexplored. This study examines acute and long-term effects of psilocybin in healthy individuals. A double-blind, placebo-controlled, cross-over study included 40 healthy participants (20 females, mean age 38). Each received two doses of...

DOI: 10.1007/s43440-025-00742-5 (opens in new tab) Full text (opens in new tab) Healthy population Previous experience Repeated administration Sex +7

A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.

Journal of Psychopharmacology June 10, 2025 Torsten Passie, Anja Loizaga-Velder, Alicia Danforth et al. 4 citations

The authors offer a model for curriculum for education and training in substance-assisted psychotherapy (SAP), that is, psychedelic, psycholytic, and entactogen/MDMA (3,4-methylenedioxymethamphetamine)-assisted psychotherapy, addressing both the detailed contents of training and the question of experiential training. All authors of this model have an abiding interest and extensive experience in...

DOI: 10.1177/02698811241282759 (opens in new tab) Full text (opens in new tab) Psychedelic therapy MDMA-Assisted Psychotherapy Education of therapists Psycholytic therapy +7

Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium.

Journal of Psychopharmacology May 28, 2025 Yana Vella, Kateřina Syrová, Aneta Petrušková et al. 1 citation

Recent evidence suggests that psychedelics can induce rapid and long-lasting antidepressant effects. The generally acknowledged explanation for these traits is the phenomenon of neuroplasticity, although the exact underlying molecular mechanisms remain unclear. This study investigates the effects of psilocin, lysergic acid diethylamide (LSD) and N,N-dimethyltryptamine (DMT) on synaptogenesis...